Erdafitinib (Janssen Research and Development).
The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing.
Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a much-needed momentum.
Get in touch for a holistic view of the
The BTC market report also covers the market of Cholangiocarcinoma including (Intrahepatic and Extrahepatic), Gallbladder, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market s underlying potential, and plans strategically to tackle market risks.
NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells
NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors
NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3 -dATP
Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana s ProTides in clinical development were presented. Summaries of the posters are described below.
NuCana plc
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer
NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells
NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors
NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3’-dATP
Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
March 16, 2021 GMT
Not intended for UK-based media
DARMSTADT, Germany, March 16, 2021 /PRNewswire/ Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy.
In the study of 159 patients, bintrafusp alfa demonstrated single-agent efficacy and durability with a manageable safety profile after more than nine months of follow-up, with an Independent Review Committee (IRC)-adjudicated objective response rate (ORR) of 10.1% (95% CI: 5.9% to 15.8%) per RECI
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
Not intended for US-, Canada- or UK-based media
DARMSTADT, Germany, March 16, 2021 /PRNewswire/ Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy.
In the study of 159 patients, bintrafusp alfa demonstrated single-agent efficacy and durability with a manageable safety profile after more than nine months of follow-up, with an Independent Review Committee (IRC)-adjudicated objective response rate (ORR) of 10.1% (95% CI: 5.9% to 15.8%) per RECIST 1.1. Though single-agent activity was observed,